Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: J Card Fail. 2013 May;19(5):295–302. doi: 10.1016/j.cardfail.2013.03.002

Figure 2. Adjusted survival curves grouped by randomization to digoxin or placebo and subsequent improved renal function status, in patients with a serum digoxin level ≤0.8 ng/ml.

Figure 2

Improved renal function (IRF) defined as a ≥20% improvement in estimated glomerular filtration rate (eGFR) from randomization to one year. Covariates adjusted for: age, race, ejection fraction, heart rate, systolic blood pressure, NHYA class, diabetes, baseline use of digoxin, hydralazine, nitrates, diuretics, or angiotensin converting enzyme inhibitors, physical examination findings, cardio-thoracic ratio, and baseline eGFR. Overall between group differences p=0.028. Comparisons of the Yes IRF/Yes Digoxin (n=58) to the No IRF/No Digoxin group (n=409, p=0.007), No IRF/Yes Digoxin (n=213, p=0.026), and Yes IRF/No Digoxin group (n=60, p=0.004) were all statistically significant.